Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of **omega-3 fatty acids** and **folic acid** (Vitamin B9) is an investigational therapeutic regimen developed by the **Reproductive Partners Medical Group** for the treatment of male infertility. This specific formulation was evaluated in a Phase 2 clinical trial (NCT01548625) to assess its impact on sperm quality parameters—including concentration, motility, and morphology—as well as sexual function in infertile men. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential structural components of the sperm cell membrane; their incorporation is thought to enhance membrane fluidity and protect against oxidative damage. Folic acid serves as a critical cofactor in one-carbon metabolism, facilitating DNA synthesis and repair during spermatogenesis and helping to regulate homocysteine levels, which are often elevated in cases of subfertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acids + folic acid.